Neumora Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the Annual Meeting of Stockholders held by Neumora Therapeutics, Inc. on May 27, 2026. The filing details the voting outcomes for four proposals presented to stockholders of record as of April 7, 2026, when 182,688,076 shares of common stock were outstanding.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and stockholder voting results.
Material Changes and Voting Results
The following proposals were voted upon and approved:
- Proposal 1 (Election of Directors): Three Class III directors were elected to serve until the 2029 annual meeting.
- Paul L. Berns: 126,617,746 votes for; 6,076,577 withheld.
- Matthew Fust: 125,242,046 votes for; 7,452,277 withheld.
- David Piacquad: 126,878,899 votes for; 5,815,424 withheld.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Votes For: 157,623,815
- Votes Against: 53,613
- Abstentions: 43,814
- Proposal 3 (Say-on-Pay): The advisory vote on executive compensation was approved.
- Votes For: 131,998,871
- Votes Against: 420,917
- Abstentions: 274,535
- Proposal 4 (Frequency of Say-on-Pay): Stockholders voted to hold the advisory vote on executive compensation annually.
- For One Year: 124,682,414
- For Two Years: 23,968
- For Three Years: 7,948,592
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, or contingencies. The document confirms that the Company will conduct annual advisory votes on executive compensation based on the Board's recommendation and the voting results.
Key Facts for Investor Verification
- Verify the definitive proxy statement (Schedule 14A) filed on April 17, 2026, for detailed biographies of the elected directors and the full compensation discussion.
- Confirm the total number of shares outstanding (182,688,076) and the record date (April 7, 2026) to understand the voting base.
- Note the significant number of broker non-votes (25,026,919) on Proposals 1, 3, and 4, which did not affect the outcome but indicate shares held in street name where brokers lacked discretionary authority.
- Review the Company's upcoming fiscal year-end (December 31, 2026) financial reports for the first audited results under the newly ratified auditor, Ernst & Young LLP.